BURLINGTON, Mass., Dec. 8, 2010 /PRNewswire/ — Decision
Resources, one of the world’s leading research and advisory firms
for pharmaceutical and healthcare issues, finds that although
platinum-based treatment will continue to be the standard of care
for first- and second-line treatment of platinum-sensitive ovarian
cancer, pegylated liposomal doxorubicin (PLD)/carboplatin will
replace paclitaxel/carboplatin as the standard second-line
treatment for patients who remain platinum sensitive.
The Pharmacor 2010 findings from the topic entitled Ovarian
Cancer which will publish later this month reveal that, since
the publication of data last year from the CALYPSO clinical trial,
PLD (Centocor Ortho Biotech/Janssen’s Doxil, Merck’s Caelyx) is
being increasingly used in combination with carboplatin
(Bristol-Myers Squibb’s Paraplatin, generics) as an alternative to
paclitaxel (Bristol-Myers Squibb’s Taxol, generics)/carboplatin in
the second-line, platinum-sensitive population. As a result,
Decision Resources forecasts that PLD/carboplatin will replace
paclitaxel/carboplatin by 2019 as the gold-standard treatment in
this setting in the United States, France, Germany, Italy, Spain,
the United Kingdom and Japan.
According to the findings, urgent unmet need remains for
therapies that can delay or prevent progression to
platinum-resistant ovarian cancer.
“Experts we interviewed believe that such gains in addressing
unmet need will most likely come from novel targeted agents,” said
Decision Resources Analyst Niamh Murphy, Ph.D. “As such, the need
exists to identify other genetic characteristics — in addition to
BRCA1/BRCA2 mutations — that will lead to the development
of novel, molecularly targeted drugs which will benefit patients
with ovarian cancer.”
The findings also reveal that dramatic growth in the ovarian
cancer drug market through 2019 will be driven primarily by the
approval and uptake of four premium priced targeted ther
‘/>”/>